Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. IDXX
IDXX logo

IDXX Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
563.750
Open
560.590
VWAP
558.24
Vol
426.88K
Mkt Cap
44.25B
Low
548.750
Amount
238.30M
EV/EBITDA(TTM)
29.84
Total Shares
79.42M
EV
44.91B
EV/OCF(TTM)
38.00
P/S(TTM)
10.49
IDEXX Laboratories, Inc. develops, manufactures and distributes products and provides services primarily for the companion animal veterinary, livestock and poultry, dairy and water testing industries. The Company also provides human medical point-of-care and laboratory diagnostics. Its segments include Companion Animal Group (CAG), Water quality products (Water), and Livestock, Poultry and Dairy (LPD). The CAG segment offers diagnostic and information management-based products and services for the companion animal veterinary industry, including in-clinic diagnostic solutions, outside reference laboratory services, and veterinary software and services. The Water segment provides testing solutions for accurate detection and quantification of various microbiological parameters in water. The LPD segment provides diagnostic tests, services, and related instrumentation that are used to manage the health status of livestock and poultry, and to improve the quality and safety of milk.
Show More

Events Timeline

(ET)
2026-02-02
06:40:00
IDEXX Reports Q4 Revenue of $1.09B
select
2026-02-02
06:40:00
Company Sees FY26 Revenue Guidance of $4.632B to $4.72B
select
2026-01-13 (ET)
2026-01-13
09:00:00
IDEXX Laboratories Appoints Michael Erickson as New CEO
select

News

CNBC
7.5
03-29CNBC
Employers Recognize Employee Pet Care Needs
  • Emerging Employee Trend: As U.S. companies mandate a full return to office, pet care is increasingly recognized as a vital short-term support service, with approximately 59 million Americans providing family care in 2024, highlighting the strong demand for pet care.
  • Significant Absenteeism Impact: A survey by Wagmo reveals that 75% of pet owners missed work due to pet care issues in the past year, with 26% missing six or more days, indicating a direct impact on employee productivity.
  • Expanded Corporate Benefits: Wellthy introduced pet care into its back-up services in 2024, with around 50% of clients offering this benefit, showcasing innovation and adaptability in employee welfare aimed at enhancing satisfaction and retention rates.
  • Context of Caregiving Crisis: While pet care may not be the most urgent need, Wellthy's service expansion aligns with the founder's personal caregiving experiences, aiming to alleviate financial and emotional stress for families, thereby improving overall workplace productivity.
NASDAQ.COM
2.0
03-19NASDAQ.COM
Analysis of the Importance of Market Capitalization
  • Market Capitalization Comparison: Dell Technologies Inc (DELL) has a market cap of $47.50 billion, while Idexx Laboratories, Inc. (IDXX) stands at $45.95 billion, providing investors with a more accurate assessment of company value and avoiding misconceptions based solely on stock price.
  • Investor Decision Impact: Market capitalization not only affects a company's size ranking among peers but also directly influences which mutual funds and ETFs are willing to hold these stocks, as large-cap funds may focus solely on companies valued at over $10 billion.
  • Mid-Cap Performance Potential: The S&P MidCap index focuses on smaller companies by excluding the largest 100 firms, allowing mid-cap stocks to potentially outperform larger rivals in favorable market conditions, thus offering additional investment opportunities for investors.
  • Price Performance Comparison: At Thursday's close, DELL's stock rose approximately 5.1%, while IDXX's stock increased by about 0.5%, indicating Dell's strong market performance, which may attract more investor attention to its growing market capitalization.
Yahoo Finance
9.5
03-15Yahoo Finance
Bullish Thesis on IDEXX Laboratories Stock Investment
  • Strong Profitability: IDEXX Laboratories has demonstrated earnings per share growth ranking in the top 10% over recent quarters and years, highlighting its robust profitability amid rising pet healthcare spending, which attracts investor interest.
  • Rising Market Demand: As pet owners increasingly seek advanced care, IDEXX's diagnostic business benefits from long-term growth in pet healthcare spending, which is expected to drive future revenue growth for the company.
  • Outstanding Stock Performance: IDEXX's stock price has appreciated by 60.4% over the past 52 weeks, placing it among the top 10% on a relative strength basis, reflecting its sustained revenue growth and high-margin business model.
  • Attractive Investment Opportunity: The company's strong financial performance in the pet healthcare sector and favorable demographic trends make IDEXX's stock an appealing choice for investors seeking exposure to structural growth.
Fool
6.5
03-13Fool
Bamco Inc Increases Stake in FactSet by $317.17 Million
  • Stake Increase: Bamco Inc increased its position in FactSet Research Systems by 1,069,786 shares during Q4 2025, amounting to an investment of $317.17 million, indicating confidence in the company despite a 58.2% decline in stock price over the past year.
  • Asset Allocation: FactSet now accounts for 2.27% of Bamco's 13F assets under management, highlighting its significance in Bamco's investment portfolio, even as overall market performance remains weak.
  • Financial Overview: FactSet's latest financial report shows a trailing twelve-month revenue of $2.36 billion and a net income of $599.60 million, with a dividend yield of 2.14%, indicating the company's ability to maintain profitability under a stable subscription model.
  • Market Position: As a leading provider of financial data and analytics, FactSet supports global investment decision-making through its comprehensive workflow solutions, reinforcing its role as a key partner for institutional investors despite facing market volatility challenges.
NASDAQ.COM
6.5
03-13NASDAQ.COM
Bamco Inc Increases Stake in FactSet Research Systems
  • Stake Increase: Bamco Inc increased its stake in FactSet Research Systems by 1,069,786 shares during Q4 2026, bringing its total holdings to 2,888,845 shares valued at $838.31 million, indicating strong confidence in the company.
  • Asset Management Proportion: This acquisition positions Bamco's holdings in FactSet at 2.27% of its 13F reportable assets under management, although it remains outside the top five holdings, highlighting its significance in the investment portfolio.
  • Market Performance: As of February 17, 2026, FactSet's stock price stood at $190.06, down 58.2% over the past year, underperforming the S&P 500 by 69.8 percentage points, reflecting market concerns regarding its future growth prospects.
  • Business Model Advantage: FactSet leverages a robust subscription model and comprehensive workflow solutions to continuously provide financial data and analytics to global investment professionals, ensuring stable revenue streams and strong client relationships despite market fluctuations.
Yahoo Finance
8.5
03-13Yahoo Finance
Bamco Expands FactSet Stake to $838 Million as Financial Data Platform Drives Recurring Revenue
  • Stake Increase: Bamco Inc increased its position in FactSet Research Systems by 1,069,786 shares during Q4 2025, amounting to $317.17 million, which now represents 2.27% of its 13F assets under management, indicating strong confidence in the financial data platform.
  • Market Performance: As of February 17, 2026, FactSet shares were priced at $190.06, reflecting a 58.2% decline over the past year, significantly underperforming the S&P 500 by 69.8 percentage points, raising concerns about its future growth prospects.
  • Financial Overview: FactSet reported a trailing twelve-month revenue of $2.36 billion and a net income of $599.60 million, with a dividend yield of 2.14%, showcasing its stability and profitability in the financial data and analytics sector.
  • Client Base: FactSet provides integrated financial information and analytics tools for global investment professionals, relying on its subscription model to generate recurring revenue, ensuring strong client retention, particularly among asset managers and investment banks.
Wall Street analysts forecast IDXX stock price to rise
10 Analyst Rating
Wall Street analysts forecast IDXX stock price to rise
7 Buy
3 Hold
0 Sell
Moderate Buy
Current: 0.000
sliders
Low
750.00
Averages
792.78
High
850.00
Current: 0.000
sliders
Low
750.00
Averages
792.78
High
850.00
Stifel
Jonathan Block
Buy
downgrade
$775 -> $675
AI Analysis
2026-03-31
New
Reason
Stifel
Jonathan Block
Price Target
$775 -> $675
AI Analysis
2026-03-31
New
downgrade
Buy
Reason
Stifel analyst Jonathan Block lowered the firm's price target on Idexx Laboratories to $675 from $775 and keeps a Buy rating on the shares. The firm continues to view Idexx as more of a second half story, the analyst tells investors.
Piper Sandler
Neutral
downgrade
$775 -> $750
2026-02-09
Reason
Piper Sandler
Price Target
$775 -> $750
2026-02-09
downgrade
Neutral
Reason
Piper Sandler lowered the firm's price target on Idexx Laboratories to $750 from $775 and keeps a Neutral rating on the shares following quarterly results. The firm says its updated price target primarily reflects its updated multiple and rolling forward of estimates to 2027 from 2026.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for IDXX
Unlock Now

Valuation Metrics

The current forward P/E ratio for IDEXX Laboratories Inc (IDXX.O) is 47.56, compared to its 5-year average forward P/E of 49.88. For a more detailed relative valuation and DCF analysis to assess IDEXX Laboratories Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PE
49.88
Current PE
47.56
Overvalued PE
62.12
Undervalued PE
37.64

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average EV/EBITDA
34.92
Current EV/EBITDA
33.89
Overvalued EV/EBITDA
43.27
Undervalued EV/EBITDA
26.57

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
11.18
Current PS
11.74
Overvalued PS
13.65
Undervalued PS
8.70

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

top stocks in health sector
Intellectia · 38 candidates
Market Cap: >= 10.00BSector: Healthcare, Healthcare Services & EquipmentIndustry: Biotechnology & Medical Research, Healthcare Equipment & Supplies, Healthcare Providers & Services, PharmaceuticalsAnalyst Consensus: Strong Buy, Moderate BuyRevenue 5yr Cagr: >= 5List Exchange: XNYS, XNAS, XASEReturn On Equity: >= 10.0%
Ticker
Name
Market Cap$
top bottom
LLY logo
LLY
Eli Lilly and Co
866.87B
ABBV logo
ABBV
AbbVie Inc
364.65B
AZN logo
AZN
AstraZeneca PLC
293.00B
MRK logo
MRK
Merck & Co Inc
282.35B
UNH logo
UNH
UnitedHealth Group Inc
254.55B
AMGN logo
AMGN
Amgen Inc
188.63B
what is a good buy right now
Intellectia · 32 candidates
Analyst Consensus: Strong Buy, Moderate BuyQuarter Eps Yoy Growth: 15.0% - 100.0%Target Price Upside Potential: MoreAbovePrice, AbovePriceIs Index Component: GSPC, NDXOne Week Rise Prob: 60 - 100One Week Predict Return: 0.0% - 100.0%
Ticker
Name
Market Cap$
top bottom
TPR logo
TPR
Tapestry Inc
26.06B
BK logo
BK
Bank of New York Mellon Corp
81.14B
TTD logo
TTD
Trade Desk Inc
13.04B
GPN logo
GPN
Global Payments Inc
18.87B
MDB logo
MDB
MongoDB Inc
27.39B
MA logo
MA
Mastercard Inc
492.21B
which stock price above $100 but bearish
Intellectia · 61 candidates
Price: >= $100.00Option Sentiments: Bearish
Ticker
Name
Market Cap$
top bottom
TSM logo
TSM
Taiwan Semiconductor Manufacturing Co Ltd
1.69T
MA logo
MA
Mastercard Inc
473.76B
GE logo
GE
General Electric Co
335.96B
KLAC logo
KLAC
KLA Corp
199.72B
BLK logo
BLK
BlackRock Inc
183.61B
GEV logo
GEV
GE Vernova Inc
181.21B

Whales Holding IDXX

L
Liontrust Asset Management PLC
Holding
IDXX
+1.80%
3M Return
M
Martin Currie Ltd.
Holding
IDXX
+1.75%
3M Return
S
Stephens Investment Management Group, LLC
Holding
IDXX
+0.93%
3M Return
I
Inspire Investing, LLC
Holding
IDXX
+0.88%
3M Return
T
TimesSquare Capital Management, LLC
Holding
IDXX
+0.53%
3M Return
C
Comgest S.A.
Holding
IDXX
-2.22%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is IDEXX Laboratories Inc (IDXX) stock price today?

The current price of IDXX is 562.21 USD — it has increased 0.92

What is IDEXX Laboratories Inc (IDXX)'s business?

IDEXX Laboratories, Inc. develops, manufactures and distributes products and provides services primarily for the companion animal veterinary, livestock and poultry, dairy and water testing industries. The Company also provides human medical point-of-care and laboratory diagnostics. Its segments include Companion Animal Group (CAG), Water quality products (Water), and Livestock, Poultry and Dairy (LPD). The CAG segment offers diagnostic and information management-based products and services for the companion animal veterinary industry, including in-clinic diagnostic solutions, outside reference laboratory services, and veterinary software and services. The Water segment provides testing solutions for accurate detection and quantification of various microbiological parameters in water. The LPD segment provides diagnostic tests, services, and related instrumentation that are used to manage the health status of livestock and poultry, and to improve the quality and safety of milk.

What is the price predicton of IDXX Stock?

Wall Street analysts forecast IDXX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IDXX is792.78 USD with a low forecast of 750.00 USD and a high forecast of 850.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is IDEXX Laboratories Inc (IDXX)'s revenue for the last quarter?

IDEXX Laboratories Inc revenue for the last quarter amounts to 1.09B USD, increased 14.28

What is IDEXX Laboratories Inc (IDXX)'s earnings per share (EPS) for the last quarter?

IDEXX Laboratories Inc. EPS for the last quarter amounts to 3.08 USD, increased 17.56

How many employees does IDEXX Laboratories Inc (IDXX). have?

IDEXX Laboratories Inc (IDXX) has 11000 emplpoyees as of March 31 2026.

What is IDEXX Laboratories Inc (IDXX) market cap?

Today IDXX has the market capitalization of 44.25B USD.